{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-22-001472","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.986352+00:00","generated_at":"2026-06-22T08:13:22.302491+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Immunic Q3 net loss $21.2M; goodwill impairment ~$33M; cash $129M; IMU-935 psoriasis trial misses","bullets":["Net loss $21.2M ($0.69/share) vs $19.3M ($0.76) in Q3 2021; R&D $16.5M, G&A $3.6M.","Cash $72.8M at Sept 30; plus $56.4M net from Oct private placement => runway into Q4 2024.","Expects goodwill impairment of ~$33M in Q4 2022 due to stock decline after IMU-935 psoriasis data.","IMU-935 psoriasis phase 1b: interim data showed no separation from placebo; high placebo rate; update Q1 2023.","IMU-856 phase 1 Parts A/B positive; Part C in celiac disease ongoing, data 2023; patent allowance received."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-22-001472","json":"https://secwatch.observer/filing/0001193805-22-001472.json","markdown":"https://secwatch.observer/filing/0001193805-22-001472.md","text":"https://secwatch.observer/filing/0001193805-22-001472.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380522001472/0001193805-22-001472-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380522001472/e617987_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:13:22.302491+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a15decead885f60cd60fd66af0935bc4299fbc1f","claim":"IMMUNIC, INC. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022 and providing a corporate update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380522001472/0001193805-22-001472-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}